Follicular lymphoma - Pipeline Insight, 2021
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Follicular lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Follicular lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Follicular lymphoma: Overview
Follicular lymphoma is the most common type of low-grade non-Hodgkin lymphoma. It can develop at any age, but it is more common in people over 60. In most cases, there is no known cause for follicular lymphoma. Some genetic changes are common in follicular lymphoma, but scientists don’t know what causes them. There is not normally any family history of follicular lymphoma. Follicular lymphoma is usually very slow-growing so symptoms develop gradually over time. Many people have few symptoms and some have none at all. Sometimes follicular lymphoma is noticed during tests for a different health issue. However, follicular lymphoma can be very variable and some people might have faster-growing follicular lymphoma that causes more symptoms.
'Follicular lymphoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Follicular lymphoma pipeline landscape is provided which includes the disease overview and Follicular lymphoma treatment guidelines. The assessment part of the report embraces, in depth Follicular lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Follicular lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Follicular lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Follicular lymphoma Emerging Drugs
Further product details are provided in the report……..
Follicular lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Follicular lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
Follicular lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Follicular lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Follicular lymphoma drugs.
Follicular lymphoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Follicular lymphoma - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Follicular lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Follicular lymphoma: Overview
Follicular lymphoma is the most common type of low-grade non-Hodgkin lymphoma. It can develop at any age, but it is more common in people over 60. In most cases, there is no known cause for follicular lymphoma. Some genetic changes are common in follicular lymphoma, but scientists don’t know what causes them. There is not normally any family history of follicular lymphoma. Follicular lymphoma is usually very slow-growing so symptoms develop gradually over time. Many people have few symptoms and some have none at all. Sometimes follicular lymphoma is noticed during tests for a different health issue. However, follicular lymphoma can be very variable and some people might have faster-growing follicular lymphoma that causes more symptoms.
'Follicular lymphoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Follicular lymphoma pipeline landscape is provided which includes the disease overview and Follicular lymphoma treatment guidelines. The assessment part of the report embraces, in depth Follicular lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Follicular lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Follicular lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Follicular lymphoma.
This segment of the Follicular lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Follicular lymphoma Emerging Drugs
- Pembrolizumab: Merck & Co
- Mosunetuzumab: Genentech
- Tafasitamab: Incyte Corporation
Further product details are provided in the report……..
Follicular lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Follicular lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Follicular lymphoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Follicular lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Follicular lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Follicular lymphoma drugs.
Follicular lymphoma Report Insights
- Follicular lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Follicular lymphoma drugs?
- How many Follicular lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Follicular lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Follicular lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Follicular lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Merck & Co
- Genentech
- Incyte Corporation
- Syndax Pharmaceuticals
- Dr Reddy's Laboratories
- Novartis
- ADC Therapeutics
- Xynomic Pharmaceuticals
- Cho Pharma Inc.
- Janssen
- XEME Biopharma Inc.
- Shanghai Yingli Pharmaceutical
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Beijing Mabworks Biotech Co., Ltd.
- Archigen Biotech
- Hutchison Medipharma Limited
- Nordic Nanovector
- Xynomic Pharmaceuticals
- TG Therapeutics
- BeiGene
- Allogene Therapeutics
- MEI Pharma, Inc.
- Pfizer
- Innovent Biologics (Suzhou) Co. Ltd.
- Enterome
- AstraZeneca
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Takeda
- Bristol-Myers Squibb
- TCR2 Therapeutics
- Pembrolizumab
- Mosunetuzumab
- Tafasitamab
- Entinostat
- DRL_RI
- Tisagenlecleucel
- Loncastuximab Tesirine
- Abexinostat
- CHO-H01
- Ibrutinib
- Oncoquest-L vaccine
- YY-20394
- TQ-B3525
- MIL62
- SAIT101
- HMPL-689
- Betalutin
- Abexinostat
- Ublituximab
- Zanubrutinib
- ALLO-501
- Zandelisib
- PF-06821497
- IBI376
- EO2463
- Acalabrutinib
- SHC014748M
- TAK-659
- Nivolumab
- TC 110
Introduction
Executive Summary
Follicular lymphoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Mosunetuzumab: Genentech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Pembrolizumab: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ALLO-501: Allogene Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Follicular lymphoma Key Companies
Follicular lymphoma Key Products
Follicular lymphoma- Unmet Needs
Follicular lymphoma- Market Drivers and Barriers
Follicular lymphoma- Future Perspectives and Conclusion
Follicular lymphoma Analyst Views
Follicular lymphoma Key Companies
Appendix
Executive Summary
Follicular lymphoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Mosunetuzumab: Genentech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Pembrolizumab: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ALLO-501: Allogene Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Follicular lymphoma Key Companies
Follicular lymphoma Key Products
Follicular lymphoma- Unmet Needs
Follicular lymphoma- Market Drivers and Barriers
Follicular lymphoma- Future Perspectives and Conclusion
Follicular lymphoma Analyst Views
Follicular lymphoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Follicular lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Follicular lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Follicular lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Follicular lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
